Hepatocellular carcinoma is the most common type of liver cancer and is a leading cause of cancer-related deaths worldwide.

Despite advances in prevention techniques, screening, and new technologies in diagnosis and treatment, the incidence and mortality rates continue to rise.

Download this eBook to learn how researchers D. Li et al., leveraged IsoPlexis’ technology to study GPC3-targeted CAR-T cells and why they believe these cells represent a promising strategy for the treatment of patients with hepatocellular carcinoma.